Overview

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard B

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Antiviral Agents
Lopinavir
Ritonavir
Tipranavir